Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04581824 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04581824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04581824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
November 19, 2020
Completion date
September 10, 2024
Enrollment
243 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell